Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

There were no studies available in which the toxicokinetic properties (absorption, distribution, metabolism, elimination) of 2,3-Epoxypropyl neodecanoate, oligomeric reaction products with toluene-4-sulfonic acid were investigated.

Based on the molecular structure, molecular weight, water solubility, and octanol-water partition coefficient it can be expected that both, oral and dermal absorption rates are existent, distribution in the body is not wide.

The results form acute and repeated dose studies confirm that the substance has moderate absorption rates.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential

Additional information

There were no studies available in which the toxicokinetic properties (distribution, metabolism, elimination) of 2,3-Epoxypropyl neodecanoate, oligomeric reaction products with toluene-4-sulfonic acid were investigated. Therefore the following remarks on the toxicokinetics of the substance are based on physico-chemical properties of the compound and on toxicological data.

2,3-Epoxypropyl neodecanoate, oligomeric reaction products with toluene-4-sulfonic acid

is a substance having a molecular weight of >171 g/mol. It is a liquid, with limited solubility in water, a lipophilic character (log Kow = 4.1 - 4.3 at 24 °C for the copolymer and log Kow = 3.4 - 3.5 for the solvent xylene (diethylbenzene, mixed isomers), Hüls Infracor GmbH 1999). It has a very low vapour pressure, determined to be about 3.1x10-6Pa at 20 °C (Dornhagen 2012). With regard to hydrolysis, no dissolution was observed in all solubility studies at up to 1 % dissolution aid (acetone or acetonitrile)(Infracor GmbH 2000) and surface activity is not expected based on structure.

Oral and GI absorption: Due to the fact, that no dissolution could be observed, it is not expected that the substance is significantly hydrolysed in the GI tract. In an acute oral toxicity study (Hüls 1985), slight signs of toxicity were observed such as diuresis, indicating bioavailability of the substance via the oral route to some extend.

Dermal absorption: Due to the physico-chemical characteristics of the substance dermal absorption is expected. In addition, the slight skin irritating and skin sensibilizing properties (Hüls 1985 and LPT 2012) of the substance indicate some uptake and the possible damage to the skin surface may enhance penetration.Thus, an indication of dermal uptake of the substance is given. Therefore the bioavailability can be considered to be existent.

Inhalation absorption : Due to the very low vapour pressure inhalation absorption via vapour is not expected. Wherever aerosolization occurs exposure is possible and due to the lipophilic character, the substance has the potential to be well absorbed directly across the respiratory tract epithelium. However there are no indications, based on an acute and repeated dose 15 days inhalation study of systemic toxicity- and availability after inhalative exposure of the aerosol (Seibersdorf 2011 and TNO 2012). Metabolism: No indications and data on metabolism are available.

Distribution: The physico-chemical information (molecular weight, low vapour pressure, lipophilicity and lowwater solubility) indicate that the substance could be distributed to a certain amount.

Accumulative potential: Based on the physico-chemical information (log Pow, structure not containing ionisable elements and water solubility), it is concluded that the potential for bioaccumulation is low as it is not proposed for classification as PBT substance.

Excretion: Based on the physico-chemical information and the limited available data, excretion via urine (diuresis after acute oral toxicity treatment) can be expected. No further data on excretion are available

Based on the results of several mammalian in vitro genotoxicity tests (LPT 2012) all performed with and without metabolic activation) it is concluded that DNA-reactive metabolites of the substance will not be generated in mammals in the course of hepatic biotransformation.